The European Commission’s Beating Cancer Plan has put forth a series of initiatives designed to build a comprehensive strategy for the prevention, detection, and treatment of cancer in Europe. The EU Cancer Screening Scheme, a flagship initiative of the Beating Cancer Plan, seeks to update 2003 screening recommendations to include the latest scientific evidence and potentially extend screening recommendations and requirements to include lung cancer and others previously not included.
As part of that effort, the commission put out a call for cancer screening related evidence. In response, IASLC has issued a response strongly recommending that targeted lung cancer screening, through low-dose CT (LDCT), be included in the forthcoming EU recommendations.
“We feel that the clinical, economic, and implementation research on LDCT has sufficient scientific evidence to justify this recommendation,” IASLC said in its response, which was written by the following members on behalf of the association’s Early Detection & Screening Committee.
- John Field, MD, University of Liverpool, United Kingdom
- David Baldwin, MD, Nottingham University Hospitals, United Kingdom
- Rudolf Huber, MD, University of Munich, Germany
- Witold Ryzman, MD, Medical University of Gdansk, Poland
- Stephen Lam, MD, British Columbia Cancer Agency, Canada
- Martin C. Tammemägi, MD, PhD, Cancer Care Ontario, Canada
- Ricardo Sales dos Santos, MD, Hospital Israelita Albert Einstein, Brazil
- Anant Mohan, MD, All India Institute of Medical Sciences, India
- Chi-Fu Yang, MD, Harvard Medical School, United States
- Lucia Viola, MD, Fundacion Neumologica Colombiana, Columbia
- Betty Tong, MD, Duke University, United States
- Nir Peled, MD, Soroka Medical Center, Israel
- Andrea Borondy Kitts, Patient Advocate, United States
- Dawei Yang, MD, Zhongshan Hospital Fudan University, China
- David Yanklevitz, MD, Mount Sinai School of Medicine, United States
Read the association’s full response here.
